



(12) Translation of
European patent specification

(11) NO/EP 3608337 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/28 (2006.01)
A61P 35/00 (2006.01)
C07K 16/30 (2006.01)
C07K 16/32 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.06.17
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.04.17
(86)	European Application Nr.	19172443.4
(86)	European Filing Date	2015.08.03
(87)	The European Application's Publication Date	2020.02.12
(30)	Priority	2014.08.04, EP, 14179764 2015.06.05, EP, 15170866
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Validation States:	MA
(62)	Divided application	EP3177643, 2015.08.03
(73)	Proprietor	F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Sveits
(72)	Inventor	AST, Oliver, c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren, Sveits BACAC, Marina, c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren, Sveits IMHOF-JUNG, Sabine, c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg, Tyskland NEUMANN (formally JAEGER), Christiane, c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren, Sveits KLEIN, Christian, c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren, Sveits KLOSTERMANN, Stefan, c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg, Tyskland MOLHOJ, Michael, c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg, Tyskland REGULA, Joerg Thomas, c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg, Tyskland SCHAEFER, Wolfgang, c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg, Tyskland UMAÑA, Pablo, c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren, Sveits
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, C. J. Hambros plass 2, 0164 OSLO, Norge

(54) Title **BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES**

(56) References

Cited:

EP-A1- 2 647 707
 WO-A1-2015/150447
 WO-A1-2014/081955
 WO-A1-2009/089004
 CHRISTIAN KLEIN ET AL: "Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies", MABS, vol. 4, no. 6, November 2012 (2012-11), pages 653-663, XP055106060, ISSN: 1942-0862, DOI: 10.4161/mabs.21379
 DATABASE Geneseq [Online] 8 May 2014 (2014-05-08), "humanized GA101 antibody heavy chain variable (VH) region, SEQ ID 7.", XP002747366, retrieved from EBI accession no. GSP:BBE23702 Database accession no. BBE23702
 DATABASE Geneseq [Online] 8 May 2014 (2014-05-08), "humanized GA101 antibody light chain region, SEQ ID 10.", XP002747365, retrieved from EBI accession no. GSP:BBE23705 Database accession no. BBE23705
 DATABASE Geneseq [Online] 5 June 2014 (2014-06-05), "Anti-CD3 antibody CH2527 (VH_3-23(12)) VH, SEQ 169.", XP002747364, retrieved from EBI accession no. GSP:BBF28771 Database accession no. BBF28771
 W. SCHAEFER ET AL: "Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 27, 20 June 2011 (2011-06-20), pages 11187-11192, XP055241993, ISSN: 0027-8424, DOI: 10.1073/pnas.1019002108
 DATABASE Geneseq [Online] 5 June 2014 (2014-06-05), "Anti-CD3 antibody CH2527 (VL_7-46(13)) VL, SEQ 173.", XP002747363, retrieved from EBI accession no. GSP:BBF28775 Database accession no. BBF28775

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. T-celle-aktiverende bispesifikt antigenbindende molekyl, hvor molekylet omfatter en tungkjede ifølge SEQ ID NO: 18, en tungkjede ifølge SEQ ID NO: 19, to lettkjeder ifølge SEQ ID NO: 20 og en lettkjede ifølge SEQ ID NO: 21; og hvor tung- og lettkjedene er satt sammen for å danne et første Fab-molekyl som spesifikt binder til CD20, et andre Fab-molekyl som spesifikt binder til CD3 og et tredje Fab-molekyl som spesifikt binder til CD20, og et Fc-domene som består av en første og en andre underenhet som er i stand til stabil assosiasjon.